8-K: Endo Reports First-Quarter 2025 Financial Results and Reaffirms 2025 Financial Guidance

Endo, Inc. reports a 6% decrease in total revenues for the first quarter of 2025 but reaffirms its full-year financial guidance.

Summary

• Endo, Inc. announced its financial results for the first quarter ended March 31, 2025.
• Total revenues decreased by 6% to $393 million compared to $420 million in the first quarter of 2024, primarily due to competitive pressure in the Sterile Injectables and Generic Pharmaceuticals segments.
• Net loss decreased to $129 million from $154 million in the prior year, driven by decreased expenses related to the Chapter 11 reorganization process.
• Adjusted EBITDA decreased to $99 million from $146 million in the first quarter of 2024.
• XIAFLEX revenues grew by 7% to $121 million.
• The company reaffirms its 2025 revenue guidance of $1,775 to $1,860 million and adjusted EBITDA guidance of $620 to $650 million.
• Endo expects the combination with Mallinckrodt to close in the second half of 2025.
• Endo had $370 million in unrestricted cash and cash equivalents as of March 31, 2025.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While XIAFLEX shows growth and the company reaffirms guidance, overall revenue and EBITDA are down, indicating ongoing challenges. The Mallinckrodt merger adds uncertainty.

Positives

• XIAFLEX revenues increased by 7% compared to the first quarter of 2024, driven by volume growth.
• Net loss decreased from $154 million to $129 million year-over-year.
• The company is reaffirming its full-year 2025 financial guidance.
• The company advanced its sterile injectables pipeline through increased adoption of ADRENALIN ready-to-use premixed bags and the completion of three FDA submissions.

Negatives

• Total revenues decreased by 6% compared to the first quarter of 2024.
• Adjusted EBITDA decreased from $146 million to $99 million year-over-year.
• Sterile Injectables segment revenues decreased by 27% due to competitive pressure on VASOSTRICT and ADRENALIN vials.
• Generic Pharmaceuticals segment revenues decreased by 4% due to competitive pressure on dexlansoprazole delayed-release capsules and several other products.
• International Pharmaceuticals segment revenues decreased by 24% due to the expiration of a license to distribute a product.

Risks

• Competitive pressure in the Sterile Injectables and Generic Pharmaceuticals segments is negatively impacting revenue.
• The company's financial performance is subject to various risks and uncertainties, including those related to competition, regulatory conditions, and litigation.
• The company's ability to achieve its financial guidance is dependent on various assumptions and estimates, which may not materialize.
• The combination with Mallinckrodt is subject to regulatory and shareholder approvals, and may not be completed on the expected timeline or at all.
• The company's cash position decreased from $387 million to $370 million during the quarter.

Future Outlook

Endo reaffirms its full-year 2025 financial guidance, with expected revenues between $1,775 and $1,860 million and adjusted EBITDA between $620 and $650 million. The company anticipates the combination with Mallinckrodt to close in the second half of 2025.

Management Comments

• Scott Hirsch, Endo's Interim CEO, stated that the company remains focused on executing its growth drivers, as evidenced by strong XIAFLEX performance and the advancement of the Sterile Injectables pipeline.
• Mr. Hirsch also noted that the first-quarter results met internal expectations across all segments, leading to the reaffirmation of full-year 2025 earnings guidance.

Industry Context

The pharmaceutical industry is facing increasing competitive pressures, particularly in the generic and sterile injectables segments. Endo's results reflect these trends, with revenue declines in these areas. The proposed combination with Mallinckrodt is aimed at creating a more diversified and scaled pharmaceutical company to better compete in the market.

Comparison to Industry Standards

• Comparing Endo's performance to competitors requires considering the specific segments in which it operates.
• For example, Teva Pharmaceuticals, a major player in generic pharmaceuticals, has also faced pricing pressures and revenue declines in recent years.
• In the sterile injectables market, companies like Pfizer (through its Hospira acquisition) and Mylan (now Viatris) are key competitors.
• Endo's XIAFLEX competes in a niche market with limited direct comparables, making its 7% growth a positive sign.
• However, the overall decline in revenue and adjusted EBITDA suggests that Endo is facing challenges in maintaining profitability amidst industry headwinds.

Management Changes

Stakeholder Impact

• Shareholders will be impacted by the proposed combination with Mallinckrodt, with Endo shareholders owning 49.9% of the combined company.
• Employees may be affected by the integration of Endo and Mallinckrodt, as well as the potential separation of the generics and sterile injectables businesses.
• Customers may experience changes in product availability and pricing as a result of the combination.
• Suppliers and creditors may be impacted by the financial performance of the combined company.

Next Steps

• Endo intends to hold its 2025 Annual Meeting of Stockholders on June 25, 2025.
• The company will seek shareholder and regulatory approvals for the proposed combination with Mallinckrodt, expected to close in the second half of 2025.
• Endo will continue to execute its growth drivers and advance its Sterile Injectables pipeline.

Key Dates

Keywords

financial results, earnings release, XIAFLEX, EBITDA, revenue, Endo, Mallinckrodt, Sterile Injectables, Generic Pharmaceuticals